Skip to main content

Beam Therapeutics Inc.

BEAM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001745999

In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Beam Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $2.19M in total
Insiders trading
2
Net value
−$2.19M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Beam Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Beam Therapeutics Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ciaramella GiuseppePresident130,504Sep 25, 20266
Simon AmyChief Medical Officer85,696Jul 29, 20266
Evans John M.CEO1,047,205Jul 1, 20265
FMR LLC10% Owner, Other: See Remark 1854,583IndirectJun 29, 20263
Maraganore JohnDirector–Jun 5, 20261
Cooper Graham KDirector0Jun 5, 20261
Walsh Kathleen EDirector–Jun 5, 20261
Shaw ChristiDirector–Jun 5, 20261
Guindo ChirfiDirector–Jun 5, 20261
Fishman MarkDirector–Jun 5, 20261
Bellon ChristineChief Legal Officer109,711Apr 6, 20267
Cavanagh Bethany JSVP, Finance and Treasurer51,171Apr 6, 20266
Emany Sravan KumarChief Financial Officer105,456Apr 2, 20263
Ho CaroleDirector–Jun 6, 20250
Burrell Terry-AnnChief Financial Officer82,637Apr 29, 20240
Burow KristinaDirector12,067Jun 8, 20230
Crandell Keith10% Owner28,111Jul 2, 20210
Nelsen Robert10% Owner28,111Jul 2, 20210
Bybee Clinton10% Owner28,111Jul 2, 20210
ARCH Venture Fund IX, L.P.10% Owner28,111Jul 2, 20210
ARCH Venture Fund IX Overage, L.P.10% Owner28,111Jul 2, 20210
ARCH Venture Partners IX Overage, L.P.10% Owner28,111Jul 2, 20210
ARCH Venture Partners IX, L.P.10% Owner28,111Jul 2, 20210
ARCH Venture Partners IX, LLC10% Owner28,111Jul 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 2, 2021 (view filing)Jun 302 daysBurrell Terry-AnnCFOSSale−30.0K$122.00−$3.66M−54.7%24.8K after2 lots
Jul 8, 2021 (view filing)Jul 62 daysCooper Graham KDirectorSSale−2.61K$120.61−$315.3K−100.0%0 after12 lots
Jul 8, 2021 (view filing)Jul 71 dayEvans John M.CEOSSale−25.0K$107.87−$2.70M−2.4%1.02M after13 lots
Aug 20, 2021 (view filing)Aug 191 dayEvans John M.CEOSSale−20.0K$99.49−$1.99M−9.0%203.0K after6 lots
Oct 8, 2021 (view filing)Oct 62 daysEvans John M.CEOSSale−27.7K$83.80−$2.32M−2.6%1.03M after4 lots
Oct 8, 2021 (view filing)Oct 62 daysEvans John M.CEOSSale−20.0K$83.80−$1.68M−9.9%183.0K after4 lots
Dec 22, 2021 (view filing)Dec 20-212 daysCiaramella GiuseppePresident & CSOSSale−29.4K$85.62−$2.52M−31.9%62.8K after3 lots
Dec 23, 2021 (view filing)Dec 221 dayCiaramella GiuseppePresident & CSOSSale−2.61K$86.13−$224.5K−4.0%62.8K after3 lots
Feb 2, 2022 (view filing)Jan 312 daysEvans John M.CEOSSale−30.0K$66.83−$2.00M−3.1%938.8K afterAmended6 lots
Feb 2, 2022 (view filing)Jan 312 daysEvans John M.CEOSSale−20.0K$66.85−$1.34M−10.9%163.0K afterAmended6 lots
Apr 4, 2022 (view filing)Mar 314 daysBurrell Terry-AnnCFOSSale−1.79K$59.11−$105.6K−4.5%38.3K after
Apr 4, 2022 (view filing)Mar 314 daysEvans John M.CEOSSale−6.26K$59.11−$370.1K−0.6%1.09M after
Apr 4, 2022 (view filing)Mar 314 daysCiaramella GiuseppePresident & CSOSSale−1.86K$59.11−$109.9K−1.6%115.6K after
Apr 14, 2022 (view filing)Apr 131 dayFMR LLC10% Owner, Other: See Remark 1SSale−19.5K$50.41−$981.2K−100.0%0 after4 lots
May 2, 2022 (view filing)Apr 284 daysEvans John M.CEOSSale−30.0K$37.98−$1.14M−2.6%1.12M after5 lots
May 2, 2022 (view filing)Apr 284 daysEvans John M.CEOSSale−20.0K$37.98−$759.6K−12.3%143.0K after5 lots
Jul 29, 2022 (view filing)Jul 281 dayEvans John M.CEOSSale−30.0K$65.75−$1.97M−2.7%1.09M after5 lots
Jul 29, 2022 (view filing)Jul 281 dayEvans John M.CEOSSale−20.0K$65.78−$1.32M−14.0%123.0K after4 lots
Aug 8, 2022 (view filing)Aug 53 daysFMR LLC10% Owner, Other: See Remark 1SSale−20.3K$60.50−$1.23M−100.0%0 after2 lots
Sep 8, 2022 (view filing)Sep 62 daysFMR LLC10% Owner, Other: See Remark 1SSale−551$54.25−$29.9K−100.0%0 after
Nov 2, 2022 (view filing)Oct 312 daysEvans John M.CEOSSale−30.0K$46.30−$1.39M−2.8%1.06M after4 lots
Nov 2, 2022 (view filing)Oct 312 daysEvans John M.CEOSSale−20.0K$46.36−$927.2K−16.3%103.0K after4 lots
Dec 14, 2022 (view filing)Dec 122 daysCiaramella GiuseppePresident & CSOSSale−51.0K$42.70−$2.18M−35.8%91.5K afterFrom original3 lots
Jan 5, 2023 (view filing)Jan 32 daysCiaramella GiuseppePresident & CSOSSale−53.7K$37.46−$2.01M−35.9%96.0K after4 lots
Jan 20, 2023 (view filing)Jan 182 daysBurrell Terry-AnnChief Financial OfficerSSale−47.2K$45.14−$2.13M−60.1%31.3K after
Jan 25, 2023 (view filing)Jan 23-242 daysBurrell Terry-AnnChief Financial OfficerSSale−20.2K$45.01−$910.9K−39.3%31.3K after2 lots
Jan 30, 2023 (view filing)Jan 26-274 daysBurrell Terry-AnnChief Financial OfficerSSale−37.3K$45.08−$1.68M−54.4%31.3K after2 lots
Apr 5, 2023 (view filing)Apr 3-42 daysBurrell Terry-AnnChief Financial OfficerSSale−4.64K$29.74−$138.0K−9.0%47.1K after2 lots10b5-1
Apr 5, 2023 (view filing)Apr 3-42 daysSimon AmyChief Medical OfficerSSale−16.1K$29.87−$480.9K−18.8%69.3K after3 lots10b5-1
Apr 5, 2023 (view filing)Apr 3-42 daysBellon ChristineChief Legal OfficerSSale−2.09K$29.63−$62.0K−2.5%82.8K after2 lots10b5-1
Apr 5, 2023 (view filing)Apr 3-42 daysCiaramella GiuseppePresident & CSOSSale−3.67K$29.73−$109.2K−3.2%112.3K after2 lots10b5-1
Apr 5, 2023 (view filing)Apr 3-42 daysEvans John M.CEOSSale−11.7K$29.63−$345.3K−1.0%1.12M after2 lots10b5-1
Jul 25, 2023 (view filing)Jul 21-244 daysCiaramella GiuseppePresident and CSOSSale−156.5K$32.06−$5.02M−76.4%48.3K after2 lots10b5-1
Aug 9, 2023 (view filing)Jul 1030 daysLateSimon AmyChief Medical OfficerSSale−391$30.48−$11.9K−0.6%68.9K after10b5-1
Oct 4, 2023 (view filing)Oct 22 daysBellon ChristineChief Legal OfficerSSale−388$22.85−$8.87K−0.5%82.4K after10b5-1
Nov 1, 2023 (view filing)Oct 302 daysSimon AmyChief Medical OfficerSSale−3.45K$18.70−$64.5K−5.0%65.5K after10b5-1
Nov 22, 2023 (view filing)Nov 202 daysBellon ChristineChief Legal OfficerSSale−10.0K$30.50−$305.0K−10.8%82.4K after2 lots10b5-1
Jan 5, 2024 (view filing)Jan 32 daysBellon ChristineChief Legal OfficerSSale−1.91K$26.42−$50.4K−2.3%80.5K after10b5-1
Feb 2, 2024 (view filing)Jan 312 daysEvans John M.CEOSSale−60.0K$25.33−$1.52M−5.4%1.06M after10b5-1
Feb 15, 2024 (view filing)Feb 13-142 daysFMR LLCOther: See Remark 1SSale−901.6K$30.55−$27.5M−42.2%1.24M after4 lots
Apr 1, 2024 (view filing)Mar 284 daysEvans John M.CEOSSale−60.0K$33.86−$2.03M−5.7%998.3K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysCiaramella GiuseppePresidentSSale−4.53K$32.12−$145.6K−2.6%169.6K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysEvans John M.CEOSSale−18.1K$32.13−$581.6K−1.7%1.06M after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysBurrell Terry-AnnChief Financial OfficerSSale−5.45K$32.12−$174.9K−7.2%70.1K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysBellon ChristineChief Legal OfficerSSale−3.40K$32.12−$109.2K−3.1%104.6K after10b5-1
Apr 3, 2024 (view filing)Apr 1-22 daysSimon AmyChief Medical OfficerSSale−23.7K$31.02−$734.8K−25.3%70.1K after2 lots10b5-1
Jun 28, 2024 (view filing)Jun 271 dayEvans John M.CEOSSale−60.0K$24.50−$1.47M−5.7%998.3K after10b5-1
Jul 3, 2024 (view filing)Jul 1-22 daysSimon AmyChief Medical OfficerSSale−1.25K$23.28−$29.1K−1.8%68.8K after2 lots10b5-1
Oct 2, 2024 (view filing)Sep 302 daysEvans John M.CEOSSale−60.0K$24.60−$1.48M−6.0%938.7K after10b5-1
Oct 2, 2024 (view filing)Oct 11 dayCavanagh Bethany JSVP, Finance and TreasurerSSale−289$23.48−$6.79K−0.6%44.9K after10b5-1